DNAprint Genomics (DNAG)

[ann441j]

Dr. Sytkowsei on our team:

"We are pleased that Dr. Sytkowski will remain such an integral part of our Company," stated DNAPrint President and Chief Executive Officer Richard Gabriel. "As one of the foremost scientists in the field of therapeutic protein research and particularly Erythropoietin, Dr. Sytkowski will bring to bear his considerable expertise on the development and the marketing of PT-401, our lead pharmaceutical product being developed for the treatment of anemia. We look forward to working with him on this project and any future endeavors."

Dr. Sytkowski is a physician and scientist with more than 25 years of clinical and research experience in the fields of oncology, hematology, cell and molecular biology, and protein biochemistry. He is an Associate Professor in the Department of Medicine at the Harvard Medical School and a member of the Division of Hematology and Oncology at BIDMC. He has authored a book on Erythropoietin entitled "Erythropoietin: Blood, Brain and Beyond" and has authored many scientific papers and several milestone patents covering Erythropoietin. Furthermore, he has served as an expert witness and advisor to leading pharmaceutical companies selling Erythropoietin products.

DNAPrint Genomics is already working with Dr. Sytkowski and BIDMC to develop a new, more potent and longer acting form of the drug Erythropoietin (EPO) for the treatment of anemia. Under the terms of that agreement, BIDMC has granted the Company an exclusive license to United States and foreign patents related to certain forms of EPO, including PT-401.

Ann